LOGIN
ID
PW
MemberShip
2025-07-21 03:20
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Opinion
[Reporter¡¯s view] public-private consultative body
by
Lee, Jeong-Hwan
Jul 17, 2024 05:50am
During the swine flu pandemic, South Korea had a challenging time due to the Tamiflu shortage. Then, during the COVID-19 pandemic, the government spent national finances to import vaccines from the U.S., Europe, and even Russia due to the absence of local mRNA vaccines. During the COVID-19 pandemic, countries worldwide focused on locally
Opinion
[Reporter's View] Aspirations for Indication-based pricing
by
Eo, Yun-Ho
Jul 17, 2024 05:50am
The government doesn't seem to be considering it, but talks keep rising. At a recent media briefing held by the Korean Research-based Pharmaceutical Industry Association, Dong-Cheol Seo, Director of the Korea Institute for Pharmaceutical Policy Affairs (former professor at Chung-Ang University College of Pharmacy), emphasized the need for Ko
Opinion
[Desk¡¯s View] Respect Korea's generic drug industry
by
Lee, Tak-Sun
Jul 16, 2024 05:46am
&160;The Korean pharmaceutical industry is characterized by generic competition upon the original drug¡¯s patent expiry. When a new drug's patent expires, companies develop products that contain the ingredients for marketing. Combination drugs, reformulated drugs, and generic drugs containing patent-expired drug ingredients are the weapons
Opinion
[Reporter¡¯s View] MFDS provides support for drug shortages
by
Lee, Hye-Kyung
Jul 15, 2024 05:47am
A thyroid cancer treatment ¡®Theracap¡¯ was once listed on a ¡°Drug Shortages Database,¡± where suspension of the supply or shortages are listed as current, of the Ministry of Food and Drug Safety (MFDS)¡¯s Drug Safety website and then removed. Saehan Industry expected the drug shortage and notified the MFDS of its suspension in accordance w
Opinion
[Reporter¡¯s View] 'all-comers' with strict criteria
by
Eo, Yun-Ho
Jul 2, 2024 05:48am
Drugs that are intended for use regardless of any conditions are strictly regulated. In the pharmaceutical industry, 'all-comers' refers to a drug indication that can be prescribed at any treatment stage, regardless of conditions. Drugs with all-comers indications have demonstrated their efficacy regardless of receptors or genetic mu
Opinion
[Reporter¡¯s View] No innovation without failure
by
Son, Hyung-Min
Jul 1, 2024 05:47am
Korean biopharmaceutical companies are exchanging joy and sorrow over out-licensing agreements. Last month, three companies, including HK inno.N, have successfully signed agreements to out-licensing of their new drug candidates in addition to AprilBio and ISU Abxis. In contrast, there are instances where new drug candidates that have been
Opinion
[Reporter's View] No more exemptions, just deferrals
by
Eo, Yun-Ho
Jun 24, 2024 05:47am
The Korean government has set out to fix the pharmacoeconomic evaluation exemption system. Although the authorities coined it as an ¡°improvement,¡± the direction seems to be near a ¡°reduction.¡± A report on a study commissioned by the Health Insurance Review and Assessment Service was released at the end of last year. The study, titled
Opinion
[Reporter¡¯s View] Reliability Verification Review Committee
by
Lee, Hye-Kyung
Jun 20, 2024 05:48am
The Ministry of Food and Drug Safety has formed a Reliability Verification Review Committee. In the 'Guideline for Drug Manufacturing, Sales, and Import Marketing Authorizations and Labeling Change Authorizations,' which was revised by the MFDS on the 17th, a procedure was added for the Reliability Verification Review Committee to verify the
Opinion
[Reporter¡¯s View] Finances limit reimbursement of drugs
by
Eo, Yun-Ho
Jun 7, 2024 05:51am
&160;Insurance reimbursement standards and indications for a drug can differ. This is because the government¡¯s pockets are not infinite under the National Health Insurance System. This is why there are always complaints in the field. Not all complaints can be resolved but there are some that evidently require resolution, that were made
Opinion
[Reporter's View] Expectations for new Alzheimer's drugs
by
Son, Hyung-Min
Jun 5, 2024 05:47am
Last month, a new drug for Alzheimer's disease, Leqembi, was approved in Korea. Leqembi, which was developed by Eisai and Biogen, targets the amyloid beta (A¥â) protein in the brain, which is considered one of the most likely causes of Alzheimer's disease. The industry welcomed Leqembi¡¯s arrival because there had been no promising new dr
1
2
3
4
5
6
7
8
9
10
>